Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Intravitreal bevacizumab in refractory pseudophakic cystoid macular edema

Poster Details

First Author: P.Ramos PORTUGAL

Co Author(s):    J. Rosendo   K. Sousa   A. Pepo   A. Candeias     

Abstract Details



Purpose:

To describe the safety and efficacy of intravitreal bevacizumab injection in 2 patients with refractory cystoid macular edema (CME) after an uncomplicated cataract surgery (Irvine-Gass Syndrome)

Setting:

The authors describe a two case report of the ophthalmology department of the Hospital Espirito Santo de √Čvora, Portugal.

Methods:

Two patients with pseudophakic CME after an uncomplicated cataract surgery refractory to medical treatment (topical NSAIDs and topical corticosteroid). They underwent intravitreal bevacizumab injections. The main outcome measures were best-corrected visual acuity (BCVA) and retinal thickness on optical coherence tomography (OCT).

Results:

OCT confirmed the diagnosis of pseudophakic CME in both cases. The median duration of CME before treatment with intravitreal bevacizumab was 18 weeks (16-19 weeks). The initial BCVA was 20/100 in the first case and 20/50 in the second case. After 2 injections of intravitreal bevacizumab, they demonstrated improvement of BCVA (> 2 Early Treatment Diabetic Retinopathy Study [ETDRS] lines). The central macular thickness (CMT) measured with OCT was 619??m at baseline in the first case, 555??m in the second case and decreased to a mean of 295??m at the final follow-up. No ocular or systemic adverse events were observed.

Conclusions:

Intravitreal bevacizumab injections were safe and appeared to be an effective treatment of macular edema related to Irvine-Gass syndrome. Treated eyes had a significant improvement in best corrected visual acuity and decrease in macular thickness by optical coherence tomography.

Financial Disclosure:

NONE

Back to previous